Gurizzan Cristina, Cinquini Michela, Legramandi Lorenzo, Resteghini Carlo, Siano Marco, Bergamini Cristiana, Lorini Luigi, Smussi Davide, Paderno Alberto, Licitra Lisa, Bossi Paolo
Medical Oncology and Hematology Unit, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
Laboratory of Methodology of Sistematic Reviews and Guidelines production, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milano, Italy.
Ther Adv Med Oncol. 2025 Jan 10;17:17588359241288251. doi: 10.1177/17588359241288251. eCollection 2025.
A combination of chemotherapy and radiotherapy is employed in the curative and postoperative treatment of locally advanced head and neck cancers (HNC). Integrated chemoradiation (CRT) treatments result in a non-negligible rate of severe toxic effects. Treatment-related death (TRD) is a crucial topic for physicians involved in the curative treatment of HNC. This meta-analysis aimed to better address TRD in locally advanced HNC patients treated with CRT through available and relevant literature.
We performed a systematic review of the literature according to the PRISMA statement. The studies fulfilling these criteria included the following: concurrent or alternating CRT; both radical and postoperative settings; published from 2000 to 2020; involving 100+ patients; and available toxicity data. TRD was defined as death occurring from CRT start until a month from the end of CRT. Potential TRD predictors were evaluated.
In all, 65 studies were retrieved, with a total of 235 TRDs reported accounting for an overall risk rate of 1.4%. At meta-regression analysis, T stage and neutropenia grade >3 were potential predictors of higher TRD risk, both in univariate and multivariate analyses. Considering only the studies reporting at least one event, laryngeal/hypopharyngeal, oral cavity subsites and renal failure were significant predictors for TRD. The oropharyngeal subsite was protective in both analyses. None of the predictors proved to be independently correlated with TRD at multivariable analysis.
CRT in HNC resulted in 1.4% of TRDs. TRD rate reduction may imply better patient selection and more intensive supportive care programs.
化疗和放疗联合应用于局部晚期头颈癌(HNC)的根治性治疗和术后治疗。综合放化疗(CRT)治疗会导致严重毒副作用的发生率不可忽视。治疗相关死亡(TRD)是参与HNC根治性治疗的医生所关注的关键问题。本荟萃分析旨在通过现有相关文献,更好地探讨接受CRT治疗的局部晚期HNC患者的TRD情况。
我们根据PRISMA声明对文献进行了系统综述。符合这些标准的研究包括:同步或交替CRT;根治性和术后治疗两种情况;2000年至2020年发表;涉及100多名患者;以及有可用的毒性数据。TRD定义为从CRT开始至CRT结束后一个月内发生的死亡。对潜在的TRD预测因素进行了评估。
共检索到65项研究,总共报告了235例TRD,总体风险率为1.4%。在Meta回归分析中,无论是单变量还是多变量分析,T分期和中性粒细胞减少>3级都是TRD风险较高的潜在预测因素。仅考虑报告至少1例事件的研究,喉/下咽、口腔亚部位和肾衰竭是TRD的显著预测因素。在两项分析中,口咽亚部位都具有保护作用。在多变量分析中,没有一个预测因素被证明与TRD独立相关。
HNC患者接受CRT治疗导致1.4%的TRD。降低TRD率可能意味着更好的患者选择和更强化的支持性护理方案。